Cisplatin induced Acute Kidney Injury: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lily Guo and Version 1 by Kristen Mc Sweeney.

Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which has been linked to cellular uptake and efflux, apoptosis, vascular injury, oxidative and endoplasmic reticulum stress, and inflammation. Despite research efforts, pharmaceutical interventions, and clinical trials spanning over several decades, a consistent and stable pharmacological treatment option to reduce AKI in patients receiving cisplatin remains unavailable. This has been predominately linked to the incomplete understanding of CIAKI pathophysiology and molecular mechanisms involved.

  • cisplatin
  • acute kidney injury
  • nephrotoxicity
Please wait, diff process is still running!

References

  1. Potočnjak, I.; Marinić, J.; Batičić, L.; Šimić, L.; Broznić, D.; Domitrović, R. Aucubin administered by either oral or parenteral route protects against cisplatin-induced acute kidney injury in mice. Food Chem. Toxicol. 2020, 142, 111472.
  2. Huang, S.-J.; Huang, J.; Yan, Y.-B.; Qiu, J.; Tan, R.-Q.; Liu, Y.; Tian, Q.; Guan, L.; Niu, S.-S.; Zhang, Y. The renoprotective effect of curcumin against cisplatin-induced acute kidney injury in mice: Involvement of miR-181a/PTEN axis. Ren. Fail. 2020, 42, 350–357.
  3. Abd El-Kader, M.; Taha, R.I. Comparative nephroprotective effects of curcumin and etoricoxib against cisplatin-induced acute kidney injury in rats. Acta Histochem. 2020, 122, 151534.
  4. Chai, Y.; Zhu, K.; Li, C.; Wang, X.; Shen, J.; Yong, F.; Jia, H. Dexmedetomidine alleviates cisplatin-induced acute kidney injury by attenuating endoplasmic reticulum stress-induced apoptosis via the α2AR/PI3K/AKT pathway. Mol. Med. Rep. 2020, 21, 1597–1605.
  5. Kadir, A.; Sher, S.; Siddiqui, R.A.; Mirza, T. Nephroprotective role of eugenol against cisplatin-induced acute kidney injury in mice. Pak. J. Pharm. Sci. 2020, 33, 1281–1287.
  6. Hu, Z.; Zhang, H.; Yi, B.; Yang, S.; Liu, J.; Hu, J.; Wang, J.; Cao, K.; Zhang, W. VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis. Cell Death Dis. 2020, 11, 1–11.
  7. Fan, X.; Wei, W.; Huang, J.; Liu, X.; Ci, X. Isoorientin attenuates cisplatin-induced nephrotoxicity through the inhibition of oxidative stress and apoptosis via activating the SIRT1/SIRT6/Nrf-2 pathway. Front. Pharmacol. 2020, 11, 264.
  8. Zhang, Y.; Chen, Y.; Li, B.; Ding, P.; Jin, D.; Hou, S.; Cai, X.; Sheng, X. The effect of monotropein on alleviating cisplatin-induced acute kidney injury by inhibiting oxidative damage, inflammation and apoptosis. Biomed. Pharmacother. 2020, 129, 110408.
  9. Tan, R.Z.; Wang, C.; Deng, C.; Zhong, X.; Yan, Y.; Luo, Y.; Lan, H.Y.; He, T.; Wang, L. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NF-κB signaling maintained macrophage inflammation. Phytother. Res. 2020, 34, 139–152.
  10. Liang, H.; Zhang, Z.; He, L.; Wang, Y. CXCL16 regulates cisplatin-induced acute kidney injury. Oncotarget 2016, 7, 31652.
  11. Liu, H.; Baliga, R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63, 1687–1696.
  12. Mitazaki, S.; Honma, S.; Suto, M.; Kato, N.; Hiraiwa, K.; Yoshida, M.; Abe, S. Interleukin-6 plays a protective role in development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors. Life Sci. 2011, 88, 1142–1148.
  13. Ravichandran, K.; Holditch, S.; Brown, C.N.; Wang, Q.; Ozkok, A.; Weiser-Evans, M.C.; Nemenoff, R.; Miyazaki, M.; Thiessen-Philbrook, H.; Parikh, C.R. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am. J. Physiol. Ren. Physiol. 2018, 314, F356–F366.
  14. Kim, H.-J.; Lee, D.W.; Ravichandran, K.; Keys, D.O.; Akcay, A.; Nguyen, Q.; He, Z.; Jani, A.; Ljubanovic, D.; Edelstein, C.L. NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J. Pharmacol. Exp. Ther. 2013, 346, 465–472.
  15. Mukhopadhyay, P.; Horváth, B.; Kechrid, M.; Tanchian, G.; Rajesh, M.; Naura, A.S.; Boulares, A.H.; Pacher, P. Poly (ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic. Biol. Med. 2011, 51, 1774–1788.
  16. Liu, M.; Chien, C.-C.; Burne-Taney, M.; Molls, R.R.; Racusen, L.C.; Colvin, R.B.; Rabb, H. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 2006, 17, 765–774.
  17. Zhou, J.; An, C.; Jin, X.; Hu, Z.; Safirstein, R.L.; Wang, Y. TAK1 deficiency attenuates cisplatin-induced acute kidney injury. Am. J. Physiol. Ren. Physiol. 2020, 318, F209–F215.
  18. Andrade-Silva, M.; Cenedeze, M.A.; Perandini, L.A.; Felizardo, R.J.F.; Watanabe, I.K.M.; Agudelo, J.S.H.; Castoldi, A.; Gonçalves, G.M.; Origassa, C.S.T.; Semedo, P. TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury. Clin. Sci. 2018, 132, 1725–1739.
  19. Alikhan, M.A.; Summers, S.A.; Gan, P.Y.; Chan, A.J.; Khouri, M.B.; Ooi, J.D.; Ghali, J.R.; Odobasic, D.; Hickey, M.J.; Kitching, A.R. Endogenous toll-like receptor 9 regulates AKI by promoting regulatory T cell recruitment. J. Am. Soc. Nephrol. 2016, 27, 706–714.
  20. Ramesh, G.; Reeves, W.B. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Investig. 2002, 110, 835–842.
  21. Qin, Y.; Stokman, G.; Yan, K.; Ramaiahgari, S.; Verbeek, F.; De Graauw, M.; Van de Water, B.; Price, L.S. cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. Br. J. Pharmacol. 2012, 165, 1137–1150.
  22. Bellomo, R.; Kellum, J.A.; Ronco, C. Acute kidney injury. Lancet 2012, 380, 756–766.
  23. Kellum, J.A.; Unruh, M.L.; Murugan, R. Acute kidney injury. BMJ Clin. Evid. 2011, 394, 1949–1964.
  24. Lameire, N.; Van Biesen, W.; Vanholder, R. Acute kidney injury. Lancet 2008, 372, 1863–1865.
  25. Hanif, M.O.; Bali, A.; Ramphul, K. Acute renal tubular necrosis. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2020.
  26. Rahman, M.; Shad, F.; Smith, M.C. Acute kidney injury: A guide to diagnosis and management. Am. Fam. Physician 2012, 86, 631–639.
  27. Dalal, R.; Bruss, Z.S.; Sehdev, J.S. Physiology, renal blood flow and filtration. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2019.
  28. Oh, G.-S.; Kim, H.-J.; Shen, A.; Lee, S.B.; Khadka, D.; Pandit, A.; So, H.-S. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolytes Blood Press. 2014, 12, 55–65.
  29. Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin Nephrotoxicity. Toxins (Basel) 2010, 2, 2490–2518.
  30. Bennis, Y.; Savry, A.; Rocca, M.; Gauthier-Villano, L.; Pisano, P.; Pourroy, B. Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int. J. Clin. Pharm. 2014, 36, 420–429.
  31. Ozkok, A.; Edelstein, C.L. Pathophysiology of cisplatin-induced acute kidney injury. Biomed. Res. Int. 2014, 2014, 967826.
  32. Rosner, M.H.; Perazella, M.A. Acute kidney injury in the patient with cancer. Kidney Res. Clin. Pract. 2019, 38, 295.
  33. Ramesh, G.; Reeves, W.B. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Investig. 2002, 110, 835–842.
  34. Zhang, B.; Ramesh, G.; Norbury, C.; Reeves, W. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells. Kidney Int. 2007, 72, 37–44.
  35. Liu, P.; Li, X.; Lv, W.; Xu, Z. Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response. Biomed. Pharmacother. 2020, 122, 109693.
  36. Soni, H.; Kaminski, D.; Gangaraju, R.; Adebiyi, A. Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding. Ren. Fail. 2018, 40, 314–322.
  37. Ni, J.; Hou, X.; Wang, X.; Shi, Y.; Xu, L.; Zheng, X.; Liu, N.; Qiu, A.; Zhuang, S. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression. Cell Death Dis. 2019, 10, 355.
  38. Pabla, N.; Murphy, R.F.; Liu, K.; Dong, Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol Ren. Physiol. 2009, 296, F505–F511.
  39. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstädt, H.; Koepsell, H.; Piechota, H.-J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167, 1477–1484.
  40. Ciarimboli, G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014, 34, 547–550.
  41. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstadt, H.; Lanvers-Kaminsky, C.; Am Zehnhoff-Dinnesen, A.; Schinkel, A.H.; et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176, 1169–1180.
  42. Tanihara, Y.; Masuda, S.; Katsura, T.; Inui, K.-I. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem. Pharmacol. 2009, 78, 1263–1271.
  43. Ismail, R.S.; El-Awady, M.S.; Hassan, M.H. Pantoprazole abrogated cisplatin-induced nephrotoxicity in mice via suppression of inflammation, apoptosis, and oxidative stress. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2020, 393, 1–11.
  44. Hu, S.; Leblanc, A.; Gibson, A.; Hong, K.; Kim, J.; Janke, L.; Li, L.; Vasilyeva, A.; Finkelstein, D.; Sprowl, J. Identification of OAT1/OAT3 as contributors to cisplatin toxicity. Clin. Transl. Sci. 2017, 10, 412–420.
  45. Morsy, M.A.; Heeba, G.H. Nebivolol ameliorates cisplatin-induced nephrotoxicity in rats. Basic Clin. Pharmacol. Toxicol. 2016, 118, 449–455.
  46. Nakamura, T.; Yonezawa, A.; Hashimoto, S.; Katsura, T.; Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharm. 2010, 80, 1762–1767.
  47. Wen, X.; Buckley, B.; McCandlish, E.; Goedken, M.J.; Syed, S.; Pelis, R.; Manautou, J.E.; Aleksunes, L.M. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am. J. Pathol. 2014, 184, 1299–1308.
  48. Townsend, D.M.; Deng, M.; Zhang, L.; Lapus, M.G.; Hanigan, M.H. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol. 2003, 14, 1–10.
  49. Nieskens, T.T.; Peters, J.G.; Dabaghie, D.; Korte, D.; Jansen, K.; Van Asbeck, A.H.; Tavraz, N.N.; Friedrich, T.; Russel, F.G.; Masereeuw, R. Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity. Drug Metab. Dispos. 2018, 46, 592–599.
  50. Jhaveri, K.D.; Wanchoo, R.; Sakhiya, V.; Ross, D.W.; Fishbane, S. Adverse renal effects of novel molecular oncologic targeted therapies: A narrative review. Kidney Int. Rep. 2017, 2, 108–123.
  51. Marcolino, M.; Boersma, E.; Clementino, N.; Macedo, A.; Marx-Neto, A.; Silva, M.; van Gelder, T.; Akkerhuis, K.; Ribeiro, A. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann. Oncol. 2011, 22, 2073–2079.
  52. Huang, D.; Wang, C.; Duan, Y.; Meng, Q.; Liu, Z.; Huo, X.; Sun, H.; Ma, X.; Liu, K. Targeting Oct2 and P53: Formononetin prevents cisplatin-induced acute kidney injury. Toxicol. Appl. Pharmacol. 2017, 326, 15–24.
  53. Ishida, S.; Lee, J.; Thiele, D.J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA 2002, 99, 14298–14302.
  54. Bonventre, J.V.; Yang, L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 2011, 121, 4210–4221.
  55. Lin, X.; Okuda, T.; Holzer, A.; Howell, S. The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae. Mol. Pharmacol. 2002, 62, 1154–1159.
  56. Fox, E.; Levin, K.; Zhu, Y.; Segers, B.; Balamuth, N.; Womer, R.; Bagatell, R.; Balis, F. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. Oncologist 2018, 23, 762.
  57. Kuo, M.T.; Chen, H.H.; Song, I.S.; Savaraj, N.; Ishikawa, T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007, 26, 71–83.
  58. Hoffmann, E.K.; Sørensen, B.H.; Sauter, D.P.; Lambert, I.H. Role of volume-regulated and calcium-activated anion channels in cell volume homeostasis, cancer and drug resistance. Channels 2015, 9, 380–396.
  59. Osei-Owusu, J.; Yang, J.; Del Carmen Vitery, M.; Qiu, Z. Molecular biology and physiology of volume-regulated anion channel (VRAC). In Current Topics in Membranes; Elsevier: Amsterdam, The Netherlands, 2018; Volume 81, pp. 177–203.
  60. Holditch, S.J.; Brown, C.N.; Lombardi, A.M.; Nguyen, K.N.; Edelstein, C.L. Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury. Int. J. Mol. Sci. 2019, 20, 3011.
  61. Lalan, M.; Bagchi, T.; Misra, A. The Cell. In Challenges in Delivery of Therapeutic Genomics and Proteomics; Elsevier: Amsterdam, The Netherlands, 2011; pp. 1–43.
  62. Yonny, M.E.; García, E.M.; Lopez, A.; Arroquy, J.I.; Nazareno, M.A. Measurement of malondialdehyde as oxidative stress biomarker in goat plasma by HPLC-DAD. Microchem. J. 2016, 129, 281–285.
  63. Zhang, Y.; Chen, Y.; Li, B.; Ding, P.; Jin, D.; Hou, S.; Cai, X.; Sheng, X. The effect of monotropein on alleviating cisplatin-induced acute kidney injury by inhibiting oxidative damage, inflammation and apoptosis. Biomed. Pharmacother. 2020, 129, 110408.
  64. Tan, R.Z.; Wang, C.; Deng, C.; Zhong, X.; Yan, Y.; Luo, Y.; Lan, H.Y.; He, T.; Wang, L. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NF-κB signaling maintained macrophage inflammation. Phytother. Res. 2020, 34, 139–152.
  65. Mukhopadhyay, P.; Horváth, B.; Kechrid, M.; Tanchian, G.; Rajesh, M.; Naura, A.S.; Boulares, A.H.; Pacher, P. Poly (ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic. Biol. Med. 2011, 51, 1774–1788.
  66. Malik, S.; Suchal, K.; Gamad, N.; Dinda, A.K.; Arya, D.S.; Bhatia, J. Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur. J. Pharm. 2015, 748, 54–60.
  67. Furuichi, K.; Kaneko, S.; Wada, T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin. Exp. Nephrol. 2009, 13, 9–14.
  68. Liu, X.-Q.; Jin, J.; Li, Z.; Jiang, L.; Dong, Y.-H.; Cai, Y.-T.; Wu, M.-F.; Wang, J.-N.; Ma, T.-T.; Wen, J.-G. Rutaecarpine Derivative Cpd-6c Alleviates Acute Kidney Injury by Targeting PDE4B, a Key Enzyme Mediating inflammation in Cisplatin Nephropathy. Biochem. Pharmacol. 2020, 180, 114132.
  69. Mitazaki, S.; Honma, S.; Suto, M.; Kato, N.; Hiraiwa, K.; Yoshida, M.; Abe, S. Interleukin-6 plays a protective role in development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors. Life Sci. 2011, 88, 1142–1148.
  70. Liu, M.; Chien, C.-C.; Burne-Taney, M.; Molls, R.R.; Racusen, L.C.; Colvin, R.B.; Rabb, H. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 2006, 17, 765–774.
  71. Gao, Z.; Liu, G.; Hu, Z.; Li, X.; Yang, X.; Jiang, B.; Li, X. Grape seed proanthocyanidin extract protects from cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis. Mol. Med. Rep. 2014, 9, 801–807.
  72. Tan, Z.; Guo, F.; Huang, Z.; Xia, Z.; Liu, J.; Tao, S.; Li, L.; Feng, Y.; Du, X.; Ma, L. Pharmacological and genetic inhibition of fatty acid-binding protein 4 alleviated cisplatin-induced acute kidney injury. J. Cell. Mol. Med. 2019, 23, 6260–6270.
  73. Zarember, K.A.; Godowski, P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168, 554–561.
  74. Kimbrell, D.A.; Beutler, B. The evolution and genetics of innate immunity. Nat. Rev. Genet. 2001, 2, 256–267.
  75. Aderem, A.; Ulevitch, R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406, 782–787.
  76. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783–801.
  77. Godfroy, J.I., III; Roostan, M.; Moroz, Y.S.; Korendovych, I.V.; Yin, H. Isolated Toll-like receptor transmembrane domains are capable of oligomerization. PloS ONE 2012, 7, e48875.
  78. Bell, J.K.; Mullen, G.E.; Leifer, C.A.; Mazzoni, A.; Davies, D.R.; Segal, D.M. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol. 2003, 24, 528–533.
  79. Butcher, S.K.; O’Carroll, C.E.; Wells, C.A.; Carmody, R.J. Toll-like receptors drive specific patterns of tolerance and training on restimulation of macrophages. Front. Immunol. 2018, 9, 933.
  80. Zhang, D.; Zhang, G.; Hayden, M.S.; Greenblatt, M.B.; Bussey, C.; Flavell, R.A.; Ghosh, S. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004, 303, 1522–1526.
  81. Sharma, S.; Zou, W.; Sun, Q.; Grandvaux, N.; Julkunen, I.; Hemmi, H.; Yamamoto, M.; Akira, S.; Yeh, W.-C.; Lin, R. Activation of TBK1 and IKKε kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity. J. Virol. 2004, 78, 10636–10649.
  82. Patel, S. Danger-associated molecular patterns (DAMPs): The derivatives and triggers of inflammation. Curr. Allergy Asthma Rep. 2018, 18, 63.
  83. Kurup, S.P.; Tarleton, R.L. Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat. Commun. 2013, 4, 2616.
  84. Piccinini, A.; Midwood, K. DAMPening inflammation by modulating TLR signalling. Mediat. Inflamm. 2010, 2010, 672395.
  85. Bagchi, A.; Herrup, E.A.; Warren, H.S.; Trigilio, J.; Shin, H.-S.; Valentine, C.; Hellman, J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 2007, 178, 1164–1171.
  86. Yamamoto, M.; Sato, S.; Hemmi, H.; Hoshino, K.; Kaisho, T.; Sanjo, H.; Takeuchi, O.; Sugiyama, M.; Okabe, M.; Takeda, K. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301, 640–643.
  87. Mäkelä, S.M.; Strengell, M.; Pietilä, T.E.; Österlund, P.; Julkunen, I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J. Leukoc. Biol. 2009, 85, 664–672.
  88. Grassin-Delyle, S.; Abrial, C.; Salvator, H.; Brollo, M.; Naline, E.; Devillier, P. The role of toll-like receptors in the production of cytokines by human lung macrophages. J. Innate Immun. 2020, 12, 63–73.
  89. Wörnle, M.; Schmid, H.; Banas, B.; Merkle, M.; Henger, A.; Roeder, M.; Blattner, S.; Bock, E.; Kretzler, M.; Gröne, H.-J. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am. J. Pathol. 2006, 168, 370–385.
  90. Kropf, P.; Freudenberg, M.A.; Modolell, M.; Price, H.P.; Herath, S.; Antoniazi, S.; Galanos, C.; Smith, D.F.; Müller, I. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 2004, 72, 1920–1928.
  91. Shigeoka, A.A.; Holscher, T.D.; King, A.J.; Hall, F.W.; Kiosses, W.B.; Tobias, P.S.; Mackman, N.; McKay, D.B. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J. Immunol. 2007, 178, 6252–6258.
  92. Conti, F.; Spinelli, F.R.; Truglia, S.; Miranda, F.; Alessandri, C.; Ceccarelli, F.; Bombardieri, M.; Giannakakis, K.; Valesini, G. Kidney expression of toll like receptors in lupus nephritis: Quantification and clinicopathological correlations. Mediat. Inflamm. 2016, 2016.
  93. Ciferska, H.; Horak, P.; Konttinen, Y.T.; Krejci, K.; Tichy, T.; Hermanova, Z.; Zadrazil, J. Expression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys–a preliminary pilot study. Lupus 2008, 17, 580–585.
  94. Lin, M.; Yiu, W.H.; Wu, H.J.; Chan, L.Y.; Leung, J.C.; Au, W.S.; Chan, K.W.; Lai, K.N.; Tang, S.C. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23, 86–102.
  95. Srivastava, T.; Sharma, M.; Yew, K.-H.; Sharma, R.; Duncan, R.S.; Saleem, M.A.; McCarthy, E.T.; Kats, A.; Cudmore, P.A.; Alon, U.S. LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: Changes in TLR profile. J. Cell Commun. Signal. 2013, 7, 49–60.
  96. Shimada, M.; Ishimoto, T.; Lee, P.Y.; Lanaspa, M.A.; Rivard, C.J.; Roncal-Jimenez, C.A.; Wymer, D.T.; Yamabe, H.; Mathieson, P.W.; Saleem, M.A. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κ B-dependent pathway. Nephrol. Dial. Transplant. 2012, 27, 81–89.
  97. Li, D.; Zou, L.; Feng, Y.; Xu, G.; Gong, Y.; Zhao, G.; Ouyang, W.; Thurman, J.M.; Chao, W. Complement factor B production in renal tubular cells and its role in sodium transporter expression during polymicrobial sepsis. Crit. Care Med. 2016, 44, e289.
  98. Bäckhed, F.; Söderhäll, M.; Ekman, P.; Normark, S.; Richter-Dahlfors, A. Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ-and cell-specific expression of Toll-like receptors within the human urinary tract. Cell. Microbiol. 2001, 3, 153–158.
  99. Jonassen, J.A.; Kohjimoto, Y.; Scheid, C.R.; Schmidt, M. Oxalate toxicity in renal cells. Urol. Res. 2005, 33, 329–339.
  100. Yang, W.S.; Kim, J.-S.; Han, N.J.; Lee, M.J.; Park, S.-K. Toll-like receptor 4/spleen tyrosine kinase complex in high glucose signal transduction of proximal tubular epithelial cells. Cell. Physiol. Biochem. 2015, 35, 2309–2319.
  101. Han, S.J.; Li, H.; Kim, M.; Shlomchik, M.J.; Lee, H.T. Kidney proximal tubular TLR9 exacerbates ischemic acute kidney injury. J. Immunol. 2018, 201, 1073–1085.
  102. Samuelsson, P.; Hang, L.; Wullt, B.; Irjala, H.; Svanborg, C. Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect. Immun. 2004, 72, 3179–3186.
  103. Papadimitraki, E.; Tzardi, M.; Bertsias, G.; Sotsiou, E.; Boumpas, D.T. Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: Implications for the amplification of the inflammatory response. Lupus 2009, 18, 831–835.
  104. González-Guerrero, C.; Cannata-Ortiz, P.; Guerri, C.; Egido, J.; Ortiz, A.; Ramos, A.M. TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity. Arch. Toxicol. 2017, 91, 1925–1939.
  105. Alikhan, M.A.; Summers, S.A.; Gan, P.Y.; Chan, A.J.; Khouri, M.B.; Ooi, J.D.; Ghali, J.R.; Odobasic, D.; Hickey, M.J.; Kitching, A.R. Endogenous toll-like receptor 9 regulates AKI by promoting regulatory T cell recruitment. J. Am. Soc. Nephrol. 2016, 27, 706–714.
  106. Lepenies, J.; Eardley, K.S.; Kienitz, T.; Hewison, M.; Ihl, T.; Stewart, P.M.; Cockwell, P.; Quinkler, M. Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β1 in patients with chronic kidney disease. Nephron Clin. Pract. 2011, 119, c97–c104.
  107. Leemans, J.C.; Stokman, G.; Claessen, N.; Rouschop, K.M.; Teske, G.J.; Kirschning, C.J.; Akira, S.; Van der Poll, T.; Weening, J.J.; Florquin, S. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Investig. 2005, 115, 2894–2903.
  108. Verzola, D.; Cappuccino, L.; D’amato, E.; Villaggio, B.; Gianiorio, F.; Mij, M.; Simonato, A.; Viazzi, F.; Salvidio, G.; Garibotto, G. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney Int. 2014, 86, 1229–1243.
  109. Andrade-Silva, M.; Cenedeze, M.A.; Perandini, L.A.; Felizardo, R.J.F.; Watanabe, I.K.M.; Agudelo, J.S.H.; Castoldi, A.; Gonçalves, G.M.; Origassa, C.S.T.; Semedo, P. TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury. Clin. Sci. 2018, 132, 1725–1739.
  110. Park, H.J.; Stokes, J.A.; Corr, M.; Yaksh, T.L. Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice. Cancer Chemother. Pharmacol. 2014, 73, 25–34.
  111. Volarevic, V.; Markovic, B.S.; Jankovic, M.G.; Djokovic, B.; Jovicic, N.; Harrell, C.R.; Fellabaum, C.; Djonov, V.; Arsenijevic, N.; Lukic, M.L. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs. Theranostics 2019, 9, 5976.
  112. Ma, X.; Yan, L.; Zhu, Q.; Shao, F. Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway. PloS ONE 2017, 12, e0171612.
  113. Cenedeze, M.; Goncalves, G.; Feitoza, C.; Wang, P.; Damiao, M.; Bertocchi, A.; Pacheco-Silva, A.; Camara, N. The role of toll-like receptor 4 in cisplatin-induced renal injury. Transplant. Proc. 2007, 39, 409–411.
  114. Ramesh, G.; Zhang, B.; Uematsu, S.; Akira, S.; Reeves, W.B. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am. J. Physiol. Ren. Physiol. 2007, 293, F325–F332.
  115. Babolmorad, G.; Latif, A.; Pollock, N.M.; Domingo, I.K.; Delyea, C.; Rieger, A.M.; Allison, W.T.; Bhavsar, A.P. Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity. bioRxiv 2020, e51280.
  116. Dessing, M.C.; Kers, J.; Damman, J.; Leuvenink, H.G.; Van Goor, H.; Hillebrands, J.-L.; Hepkema, B.G.; Snieder, H.; Van den Born, J.; De Borst, M.H. Toll-like receptor family polymorphisms are associated with primary renal diseases but not with renal outcomes following kidney transplantation. PloS ONE 2015, 10, e0139769.
  117. Elloumi, N.; Fakhfakh, R.; Abida, O.; Ayadi, L.; Marzouk, S.; Hachicha, H.; Fourati, M.; Bahloul, Z.; Mhiri, M.; Kammoun, K. Relevant genetic polymorphisms and kidney expression of Toll-like receptor (TLR)-5 and TLR-9 in lupus nephritis. Clin. Exp. Immunol. 2017, 190, 328–339.
  118. Ducloux, D.; Deschamps, M.; Yannaraki, M.; Ferrand, C.; Bamoulid, J.; Saas, P.; Kazory, A.; Chalopin, J.-M.; Tiberghien, P. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int. 2005, 67, 2454–2461.
  119. Santos-Martins, M.; Sameiro-Faria, M.; Ribeiro, S.; Rocha-Pereira, P.; Nascimento, H.; Reis, F.; Miranda, V.; Quintanilha, A.; Belo, L.; Beirão, I. TLR4 and TLR9 polymorphisms effect on inflammatory response in end-stage renal disease patients. Eur. J. Inflamm. 2014, 12, 521–529.
  120. Farhat, K.; Riekenberg, S.; Heine, H.; Debarry, J.; Lang, R.; Mages, J.; Buwitt-Beckmann, U.; Röschmann, K.; Jung, G.; Wiesmüller, K.H. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J. Leukoc. Biol. 2008, 83, 692–701.
  121. Guan, Y.; Ranoa, D.R.E.; Jiang, S.; Mutha, S.K.; Li, X.; Baudry, J.; Tapping, R.I. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J. Immunol. 2010, 184, 5094–5103.
  122. Matsushima, N.; Tanaka, T.; Enkhbayar, P.; Mikami, T.; Taga, M.; Yamada, K.; Kuroki, Y. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. Bmc Genom. 2007, 8, 124.
  123. De Oliviera Nascimento, L.; Massari, P.; Wetzler, L.M. The role of TLR2 in infection and immunity. Front. Immunol. 2012, 3, 79.
  124. Raby, A.-C.; González-Mateo, G.T.; Williams, A.; Topley, N.; Fraser, D.; López-Cabrera, M.; Labéta, M.O. Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution–induced fibrosis. Kidney Int. 2018, 94, 346–362.
  125. Shen, Q.; Zhang, X.; Li, Q.; Zhang, J.; Lai, H.; Gan, H.; Du, X.; Li, M. TLR2 protects cisplatin-induced acute kidney injury associated with autophagy via PI3K/Akt signaling pathway. J. Cell. Biochem. 2019, 120, 4366–4374.
  126. Takahashi, A.; Kimura, T.; Takabatake, Y.; Namba, T.; Kaimori, J.; Kitamura, H.; Matsui, I.; Niimura, F.; Matsusaka, T.; Fujita, N. Autophagy guards against cisplatin-induced acute kidney injury. Am. J. Pathol. 2012, 180, 517–525.
  127. Myeku, N.; Figueiredo-Pereira, M.E. Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy association With sequestosome 1/p62. J. Biol. Chem. 2011, 286, 22426–22440.
  128. Cherra III, S.J.; Kulich, S.M.; Uechi, G.; Balasubramani, M.; Mountzouris, J.; Day, B.W.; Chu, C.T. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell Biol. 2010, 190, 533–539.
  129. Barth, S.; Glick, D.; Macleod, K.F. Autophagy: Assays and artifacts. J. Pathol. 2010, 221, 117–124.
  130. Xu, Y.; Chen, S.; Cao, Y.; Zhou, P.; Chen, Z.; Cheng, K. Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents. Eur. J. Med. Chem. 2018, 154, 253–266.
  131. Zhang, B.; Ramesh, G.; Uematsu, S.; Akira, S.; Reeves, W.B. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J. Am. Soc. Nephrol. 2008, 19, 923–932.
  132. Park, B.S.; Lee, J.-O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med. 2013, 45, e66.
  133. Haynes, L.M.; Moore, D.D.; Kurt-Jones, E.A.; Finberg, R.W.; Anderson, L.J.; Tripp, R.A. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 2001, 75, 10730–10737.
  134. Kurt-Jones, E.A.; Popova, L.; Kwinn, L.; Haynes, L.M.; Jones, L.P.; Tripp, R.A.; Walsh, E.E.; Freeman, M.W.; Golenbock, D.T.; Anderson, L.J. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 2000, 1, 398–401.
  135. Lai, C.-Y.; Strange, D.P.; Wong, T.A.S.; Lehrer, A.T.; Verma, S. Ebola virus glycoprotein induces an innate immune response in vivo via TLR4. Front. Microbiol. 2017, 8, 1571.
  136. Rashidi, N.; Mirahmadian, M.; Jeddi-Tehrani, M.; Rezania, S.; Ghasemi, J.; Kazemnejad, S.; Mirzadegan, E.; Vafaei, S.; Kashanian, M.; Rasoulzadeh, Z. Lipopolysaccharide-and lipoteichoic acid-mediated pro-inflammatory cytokine production and modulation of TLR2, TLR4 and MyD88 expression in human endometrial cells. J. Reprod. Infertil. 2015, 16, 72.
  137. Thomas, P.G.; Carter, M.R.; Atochina, O.; Da’Dara, A.A.; Piskorska, D.; McGuire, E.; Harn, D.A. Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism. J. Immunol. 2003, 171, 5837–5841.
  138. Oh, S.-M.; Park, G.; Lee, S.H.; Seo, C.-S.; Shin, H.-K.; Oh, D.-S. Assessing the recovery from prerenal and renal acute kidney injury after treatment with single herbal medicine via activity of the biomarkers HMGB1, NGAL and KIM-1 in kidney proximal tubular cells treated by cisplatin with different doses and exposure times. BMC Complementary Altern. Med. 2017, 17, 544.
  139. Ullah, M.; Liu, D.D.; Rai, S.; Concepcion, W.; Thakor, A.S. HSP70-Mediated NLRP3 Inflammasome Suppression Underlies Reversal of Acute Kidney Injury Following Extracellular Vesicle and Focused Ultrasound Combination Therapy. Int. J. Mol. Sci. 2020, 21, 4085.
  140. Rachmawati, D.; Bontkes, H.J.; Verstege, M.I.; Muris, J.; Von Blomberg, B.M.E.; Scheper, R.J.; Van Hoogstraten, I.M. Transition metal sensing by Toll-like receptor-4: Next to nickel, cobalt and palladium are potent human dendritic cell stimulators. Contact Dermat. 2013, 68, 331–338.
  141. Fenhammar, J.; Rundgren, M.; Hultenby, K.; Forestier, J.; Taavo, M.; Kenne, E.; Weitzberg, E.; Eriksson, S.; Ozenci, V.; Wernerson, A. Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep. Crit. Care 2014, 18, 488.
  142. Fenhammar, J.; Rundgren, M.; Forestier, J.; Kalman, S.; Eriksson, S.; Frithiof, R. Toll-like receptor 4 inhibitor TAK-242 attenuates acute kidney injury in endotoxemic sheep. Anesthesiol. J. Am. Soc. Anesthesiol. 2011, 114, 1130–1137.
  143. Yamada, M.; Ichikawa, T.; Ii, M.; Sunamoto, M.; Itoh, K.; Tamura, N.; Kitazaki, T. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: Synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl) cyclohex-1-ene-1-carboxylate. J. Med. Chem. 2005, 48, 7457–7467.
  144. Takashima, K.; Matsunaga, N.; Yoshimatsu, M.; Hazeki, K.; Kaisho, T.; Uekata, M.; Hazeki, O.; Akira, S.; Iizawa, Y.; Ii, M. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br. J. Pharmacol. 2009, 157, 1250–1262.
  145. Kashani, B.; Zandi, Z.; Karimzadeh, M.R.; Bashash, D.; Nasrollahzadeh, A.; Ghaffari, S.H. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: A novel synergistic approach for breast and ovarian cancers. Immunol. Res. 2019, 67, 505–516.
  146. Pedersen, G.; Andresen, L.; Matthiessen, M.; Rask-Madsen, J.; Brynskov, J. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin. Exp. Immunol. 2005, 141, 298–306.
  147. Wang, Y.; Abel, K.; Lantz, K.; Krieg, A.M.; McChesney, M.B.; Miller, C.J. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol. 2005, 79, 14355–14370.
  148. Wu, X.; Peng, S.L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. Off. J. Am. Coll. Rheumatol. 2006, 54, 336–342.
  149. Machida, H.; Ito, S.; Hirose, T.; Takeshita, F.; Oshiro, H.; Nakamura, T.; Mori, M.; Inayama, Y.; Yan, K.; Kobayashi, N. Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. Nephrol. Dial. Transplant. 2010, 25, 2430–2537.
  150. Mallavia, B.; Liu, F.; Lefrançais, E.; Cleary, S.J.; Kwaan, N.; Tian, J.J.; Magnen, M.; Sayah, D.M.; Soong, A.; Chen, J. Mitochondrial DNA stimulates TLR9-dependent neutrophil extracellular trap formation in primary graft dysfunction. Am. J. Respir. Cell Mol. Biol. 2020, 62, 364–372.
  151. Busconi, L.; Bauer, J.W.; Tumang, J.R.; Laws, A.; Perkins-Mesires, K.; Tabor, A.S.; Lau, C.; Corley, R.B.; Rothstein, T.L.; Lund, F.E. Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J. Immunol. 2007, 179, 7397–7405.
  152. Brooks, J.; Sun, W.; Chiosis, G.; Leifer, C.A. Heat shock protein gp96 regulates Toll-like receptor 9 proteolytic processing and confrimational stability. Biochem. Biophy. Res. Commun. 2012, 421, 780–784.
  153. Jiang, S.; Chen, X. Expression of high-mobility group box 1 protein (HMGB1) and toll-like receptor 9 (TLR9) in retinas of diabetic rats. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2017, 23, 3115.
  154. Saito, K.; Kukita, K.; Kutomi, G.; Okuya, K.; Asanuma, H.; Tabeya, T.; Naishiro, Y.; Yamamoto, M.; Takahashi, H.; Torigoe, T. Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE. Eur. J. Immunol. 2015, 45, 2028–2041.
  155. Urry, Z.; Xystrakis, E.; Richards, D.F.; McDonald, J.; Sattar, Z.; Cousins, D.J.; Corrigan, C.J.; Hickman, E.; Brown, Z.; Hawrylowicz, C.M. Ligation of TLR9 induced on human IL-10–secreting Tregs by 1α, 25-dihydroxyvitamin D3 abrogates regulatory function. J. Clin. Investig. 2009, 119, 387–398.
  156. Lai, L.-W.; Yong, K.-C.; Lien, Y.-H.H. Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury. Kidney Int. 2012, 81, 983–992.
  157. Humanes, B.; Camaño, S.; Lara, J.M.; Sabbisetti, V.; González-Nicolás, M.Á.; Bonventre, J.V.; Tejedor, A.; Lázaro, A. Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection. Nephrol. Dial. Transplant. 2017, 32, 1645–1655.
  158. Szlosarek, P.W.; Balkwill, F.R. Tumour necrosis factor α: A potential target for the therapy of solid tumours. Lancet Oncol. 2003, 4, 565–573.
  159. Wu, X.; Wu, M.-Y.; Jiang, M.; Zhi, Q.; Bian, X.; Xu, M.-D.; Gong, F.-R.; Hou, J.; Tao, M.; Shou, L.-M. TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells. Cancer Cell Int. 2017, 17, 13.
  160. Wang, X.; Lin, Y. Tumor necrosis factor and cancer, buddies or foes? 1. Acta Pharmacol. Sin. 2008, 29, 1275–1288.
  161. Ozkok, A.; Ravichandran, K.; Wang, Q.; Ljubanovic, D.; Edelstein, C.L. NF-κB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI). Toxicol. Lett. 2016, 240, 105–113.
  162. Ansari, M.A. Sinapic acid modulates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Biomed. Pharmacother. 2017, 93, 646–653.
  163. Zhou, J.; An, C.; Jin, X.; Hu, Z.; Safirstein, R.L.; Wang, Y. TAK1 deficiency attenuates cisplatin-induced acute kidney injury. Am. J. Physiol. Ren. Physiol. 2020, 318, F209–F215.
  164. Zhou, J.; Fan, Y.; Zhong, J.; Huang, Z.; Huang, T.; Lin, S.; Chen, H. TAK1 mediates excessive autophagy via p38 and ERK in cisplatin-induced acute kidney injury. J. Cell. Mol. Med. 2018, 22, 2908–2921.
  165. Mihaly, S.; Ninomiya-Tsuji, J.; Morioka, S. TAK1 control of cell death. Cell Death Differ. 2014, 21, 1667–1676.
  166. Faubel, S.; Lewis, E.C.; Reznikov, L.; Ljubanovic, D.; Hoke, T.S.; Somerset, H.; Oh, D.-J.; Lu, L.; Klein, C.L.; Dinarello, C.A. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 2007, 322, 8–15.
  167. Deng, J.; Kohda, Y.; Chiao, H.; Wang, Y.; Hu, X.; Hewitt, S.M.; Miyaji, T.; Mcleroy, P.; Nibhanupudy, B.; Li, S. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001, 60, 2118–2128.
  168. Lu, L.H.; Oh, D.-J.; Dursun, B.; He, Z.; Hoke, T.S.; Faubel, S.; Edelstein, C.L. Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J. Pharmacol. Exp. Ther. 2008, 324, 111–117.
  169. Tadagavadi, R.K.; Reeves, W.B. Endogenous IL-10 attenuates cisplatin nephrotoxicity: Role of dendritic cells. J. Immunol. 2010, 185, 4904–4911.
  170. Dhande, I.; Ma, W.; Hussain, T. Angiotensin AT 2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production. Hypertens. Res. 2015, 38, 21–29.
  171. Jones, V.S.; Huang, R.-Y.; Chen, L.-P.; Chen, Z.-S.; Fu, L.; Huang, R.-P. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim. Biophys. Acta Rev. Cancer 2016, 1865, 255–265.
  172. Ravichandran, K.; Holditch, S.; Brown, C.N.; Wang, Q.; Ozkok, A.; Weiser-Evans, M.C.; Nemenoff, R.; Miyazaki, M.; Thiessen-Philbrook, H.; Parikh, C.R. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am. J. Physiol. Ren. Physiol. 2018, 314, F356–F366.
  173. Akcay, A.; Nguyen, Q.; He, Z.; Turkmen, K.; Lee, D.W.; Hernando, A.A.; Altmann, C.; Toker, A.; Pacic, A.; Ljubanovic, D.G. IL-33 exacerbates acute kidney injury. J. Am. Soc. Nephrol. 2011, 22, 2057–2067.
  174. Scott, H.; Jones, D.; Pui, C. The tumor lysis syndrome. N. Engl. J. Med. 2011, 364, 1844–1854.
  175. Scheller, J.; Chalaris, A.; Schmidt-Arras, D.; Rose-John, S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta Mol. Cell Res. 2011, 1813, 878–888.
  176. Dennen, P.; Altmann, C.; Kaufman, J.; Klein, C.L.; Andres-Hernando, A.; Ahuja, N.H.; Edelstein, C.L.; Cadnapaphornchai, M.A.; Keniston, A.; Faubel, S. Urine interleukin-6 is an early biomarker of acute kidney injury in children undergoing cardiac surgery. Crit. Care 2010, 14, 1–13.
  177. Mitazaki, S.; Kato, N.; Suto, M.; Hiraiwa, K.; Abe, S. Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury. Toxicology 2009, 265, 115–121.
  178. Suchi, K.; Fujiwara, H.; Okamura, S.; Okamura, H.; Umehara, S.; Todo, M.; Furutani, A.; Yoneda, M.; Shiozaki, A.; Kubota, T. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res. 2011, 31, 67–75.
  179. Reeves, W.B. Innate Immunity in Nephrotoxic Acute Kidney Injury. Trans. Am. Clin. Climatol. Assoc. 2019, 130, 33.
  180. Mollica Poeta, V.; Massara, M.; Capucetti, A.; Bonecchi, R. Chemokines and chemokine receptors: New targets for cancer immunotherapy. Front. Immunol. 2019, 10, 379.
  181. Liang, H.; Zhang, Z.; He, L.; Wang, Y. CXCL16 regulates cisplatin-induced acute kidney injury. Oncotarget 2016, 7, 31652.
  182. Hu, Z.B.; Chen, Y.; Gong, Y.X.; Gao, M.; Zhang, Y.; Wang, G.H.; Tang, R.N.; Liu, H.; Liu, B.C.; Ma, K.L. Activation of the CXCL16/CXCR6 pathway by inflammation contributes to atherosclerosis in patients with end-stage renal disease. Int. J. Med. Sci. 2016, 13, 858.
  183. Wehr, A.; Tacke, F. The roles of CXCL16 and CXCR6 in liver inflammation and fibrosis. Curr. Pathobiol. Rep. 2015, 3, 283–290.
  184. Lehrke, M.; Millington, S.C.; Lefterova, M.; Cumaranatunge, R.G.; Szapary, P.; Wilensky, R.; Rader, D.J.; Lazar, M.A.; Reilly, M.P. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J. Am. Coll. Cardiol. 2007, 49, 442–449.
  185. Baeck, C.; Wehr, A.; Karlmark, K.R.; Heymann, F.; Vucur, M.; Gassler, N.; Huss, S.; Klussmann, S.; Eulberg, D.; Luedde, T. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012, 61, 416–426.
  186. Garcia, G.E.; Truong, L.D.; Li, P.; Zhang, P.; Johnson, R.J.; Wilson, C.B.; Feng, L. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am. J. Pathol. 2007, 170, 1485–1496.
  187. Liang, H.; Ma, Z.; Peng, H.; He, L.; Hu, Z.; Wang, Y. CXCL16 deficiency attenuates renal injury and fibrosis in salt-sensitive hypertension. Sci. Rep. 2016, 6, 28715.
  188. Wehr, A.; Baeck, C.; Ulmer, F.; Gassler, N.; Hittatiya, K.; Luedde, T.; Neumann, U.P.; Trautwein, C.; Tacke, F. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. PloS ONE 2014, 9, e112327.
  189. Sawant, K.V.; Poluri, K.M.; Dutta, A.K.; Sepuru, K.M.; Troshkina, A.; Garofalo, R.P.; Rajarathnam, K. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci. Rep. 2016, 6, 33123.
  190. Ravindran, A.; Sawant, K.V.; Sarmiento, J.; Navarro, J.; Rajarathnam, K. Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor. J. Biol. Chem. 2013, 288, 12244–12252.
  191. Kinsey, G.R.; Okusa, M.D. Role of leukocytes in the pathogenesis of acute kidney injury. Crit. Care 2012, 16, 1–5.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback